Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.11.02.763436

ANABOLIC FAILURE, NOT CATABOLIC ACTIVATION, UNDERLIES GLYCOGEN DEPLETION IN CERVICAL CARCINOGENESIS: A MULTI-COHORT TRANSCRIPTOMIC ANALYSIS

Abstract

Abstract Background. Cervical epithelium loses its glycogen as disease grade rises, an observation old enough to underpin iodine-based visual screening, but which arm of glycogen metabolism accounts for the loss has not been established. The expectation from cancer metabolism is catabolic: that stored glycogen is mobilized and glycolysis activated. Methods. We analyzed 238 specimens from four publicly available cohorts across three sample types: 128 laser-capture-microdissected epithelial samples, 35 bulk-tissue samples, and 75 exfoliated cytology samples in two sets (44 and 31; GSE27678). We prespecified a 33-gene panel comprising four modules: glycogen synthesis, glycogen degradation, glycolysis, and squamous differentiation. For each specimen, we calculated module scores using single-sample gene set enrichment. Differential expression was assessed with limma, pathway enrichment with fgsea, and classification performance with bootstrap confidence intervals for ROC curves. We documented all analytical decisions and their rationale. Results. Synthesis and differentiation fell with grade in all four cohorts, while degradation and glycolysis stayed at their normal-tissue baseline. All seven differentiation genes were reduced in carcinoma, and all seven occupied the top 5.1% of the ranked transcriptome, with CRNN the most down-regulated of 21,755 genes. Synthesis failed selectively, through GYS2 and PPP1R3C only, with the ubiquitous synthase GYS1 unchanged. The glycolytic module separated from normal epithelium at no grade (p 0.45 to 0.62), classified CIN3 or worse at an area under the curve of 0.569 with an interval spanning chance, and showed no enrichment in carcinoma. Synthesis separated from normal first, at CIN2, and differentiation at CIN3. The composite index tracked grade in the discovery cohort (Spearman rho 0.652, p 7.9e-17) but offered no discriminatory advantage over its differentiation component alone (0.832 against 0.832). Conclusions. Glycogen depletion in cervical carcinogenesis reflects failure of a tissue-restricted synthetic axis, GYS2 and PPP1R3C, within a collapsing squamous differentiation program, not catabolic activation. Measuring all four candidate mechanisms on one scale in the same specimen is what allows the catabolic explanation to be excluded rather than merely left untested. The pattern holds across two array chemistries and three specimen preparations, including the exfoliated cytology that screening already collects, and the synthesis and differentiation modules together are the molecular counterpart of what iodine staining reports. These are transcript-level findings and define no clinical threshold.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ajayi, O. O., Odigie, E. B., Adesite, S. O., Erameh, T., Archibong, A. M., Eziagu, U. B.. 2026-11-03. ANABOLIC FAILURE, NOT CATABOLIC ACTIVATION, UNDERLIES GLYCOGEN DEPLETION IN CERVICAL CARCINOGENESIS: A MULTI-COHORT TRANSCRIPTOMIC ANALYSIS. https://doi.org/10.64898/2026.11.02.763436

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sisyphus at the splenic flexure: sidedness in colorectal cancer

Colorectal cancer is divided into left and right to guide prognosis and therapy, yet a precise definition of left vs right sided colorectal cancer is still not fully agreed upon. The published conventions place it anywhere between the cecum and the rectosigmoid junction. The dichotomy assumes side homogeneity, i.e., that colorectal subsites within a side add limited information once the side is known. That assumption has been examined primarily through mutation prevalence, a quantity that confounds how often a driver arises with how strongly it is selected once it has. Analyzing 1,027 whole-exome and whole-genome sequenced colorectal tumors, we decomposed the prevalence of six driver groups into mutation supply and cancer effect, and asked whether a binary side label captures how each of their prevalence, mutation supply, and cancer effect vary along the colorectum. Mostly it does: the mutational input behaves as two blocks, and even the more than thirty-fold strengthening of cancer effect on BRAF V600E from sigmoid colon to cecum is adequately captured by side. But APC shows nominal evidence against side homogeneity in both prevalence and cancer effect while showing little net left-right difference, and PIK3CA H1047 rejects it in supply. The evidence for finer resolution is real but partial, and the failures do not announce themselves. We recommend additional research recording primary tumor location at the finest practicable resolution--at minimum, International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography. Such well-annotated datasets would enable the left-right boundary to be a reversible analytic choice rather than an irreversible annotation.

cancer biology↗

GATA2 SUMOylation Regulates GATA2 Stability to Control Uterine Serous Carcinoma Invasion

Uterine serous carcinoma (USC) is an aggressive uterine cancer subtype that rapidly invades the uterine myometrium and is responsible for 40% of uterine cancer deaths. The molecular mechanisms that underlie this aggressive phenotype are poorly understood. We reported recently that USC tumors with low expression of the zinc-finger transcription factor GATA Binding Protein 2 (GATA2) exhibit aggressive tissue invasion, while retention of GATA2 expression is an independent predictor of 100% recurrence-free and cancer-specific survival in patients with early-stage USC. Here, we explored the mechanism of GATA2 loss in USC tumors that portend invasion. We show that GATA2 in human USC cell lines has a rapid 128-minute protein half-life due to post-translational SUMOylation, which targets GATA2 for ubiquitin-dependent proteasomal degradation. Treatment with small-molecule SUMOylation inhibitors, siRNA-mediated depletion of SUMO-2/3, or mutation of GATA2 K222 and K389 increases GATA2 levels and suppresses invasion in USC cell lines and USC tumor spheroids without impacting cell proliferation or viability. Primary USC tumors from newly diagnosed patients show markedly increased SUMO-2/3 levels and upregulation of SUMOylation pathways compared to other uterine cancer subtypes or benign endometrium, and heat-shock mediated induction of USC SUMO signaling leads to a SUMOylation-dependent reduction in GATA2 levels. Our results implicate SUMOylation as a dynamic regulator of USC GATA2 levels and support a model in which stress-related increases in SUMO activity deplete GATA2 to drive USC invasion. Our findings also raise the possibility that small-molecule SUMOylation inhibitors may benefit patients with early-stage USC disease.

cancer biology↗

SLC25A39 loss disrupts mitochondrial redox homeostasis and exposes therapeutic vulnerabilities in glioblastoma

Glioblastoma is an incurable brain tumour characterised by extensive hypoxia and phenotypic plasticity, both of which drive therapy resistance. Mitochondrial glutathione, dependent on the inner membrane carrier SLC25A39, is central to buffering the oxidative stress that hypoxia generates; its regulation and significance in glioblastoma are nonetheless unknown. We find that SLC25A39 expression is hypoxia-inducible and HIF-dependent, enriched in hypoxic tumour niches and heterogeneously expressed within and between tumours. Its loss depletes mitochondrial glutathione, causing oxidative damage to nucleic acids and lipids, mitochondrial hyperfusion, impaired respiration and a compensatory shift towards glycolysis, glutamine catabolism and serine synthesis. SLC25A39-deficient cells grow poorly, yet resist temozolomide while becoming markedly sensitive to navitoclax, an inhibitor of Bcl-2 and Bcl-xL, which increases cell killing when combined with radiation and temozolomide. In this work, we identify SLC25A39 as a metabolic vulnerability and candidate stratification marker in glioblastoma.

cancer biology↗